Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of H008 tablets versus lansoprazole in reflux esophagitis
ChiCTR2100043456Phase 3Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of keverprazan and lansoprazole in erosive esophagitis (EE) (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Healing of reflux esophagitis. Started Jul 2020; status: recruiting.
02
Drugs
keverprazanlansoprazole
03
Conditions
erosive esophagitis (EE)
Beyond the preview
Go deeper on ChiCTR2100043456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043456.